AME has been an effective leader in professional online education. This program will offer professional education opportunities to support the continued practice adoption of recommendations made in the 2023 ACC/AHA/ACCP/ HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. It provides an opportunity to hear from clinical experts and global key opinion leaders in AF, and to discuss oral anticoagulation related issues in light of the latest Guidelines and the nuances involved.
Discuss the pathophysiology and causative factors behind a trial fibrillation related systemic thromboembolism, including regional and systemic mechanisms and the differences between rheumatic and non-valvular AF
Describe the guideline evidence-based treatment strategies for atrial fibrillation and define the strengths and weaknesses of medical management (rate vs rhythm) and anticoagulation along AF disease spectrum
Define the gaps in atrial fibrillation care continuum and the interplay of various social determinants of health and potential strategies to curb these disparities.
Evaluate an appropriate screening strategy for patients at risk for atrial fibrillation and describe suitable strategies for stroke prophylaxis and managing comorbidities.
Discuss appropriate anticoagulation strategies for treating patients with atrial fibrillation and determine how the approach should be tailored to consider comorbidities In various demographic groups.
Director of the Program
Moderator
Moderator
Speaker
Pathophysiology of Stroke and Systemic Thromboembolism.
Speaker
Evolution of the use of Oral anticoagulants for non-valvular Atrial Fibrillation.
Speaker
Overview of gaps in the knowledge and the use of anticoagulation in clinical practice.
Speaker
Future of Oral Anticoagulation Maximizing Safety & Efficacy.
Speaker
Updates on Current guidelines on the use of OAC.
Speaker
Pathophysiology of Stroke and Systemic Thromboembolism.
Speaker
Evolution of the use of Oral anticoagulation for Non-Valvular Atrial Fibrillation.
Speaker
Overview of gaps in the knowledge and the use of anticoagulation in clinical practice.
Speaker
Future of Oral Anticoagulation Maximizing Safety & Efficacy.
Speaker
Updates on Current guidelines on the use of OAC.
Based on current literature, AF has risen to be one of the most impactful cardiovascular condition that imparts tremendous morbidity, economic stress and even mortality. Appropriate & timely diagnosis, stroke prophylaxis and rhythm control are vital to improved outcomes. Early diagnosis & prompt treatment remain a gap in the AF care continuum. Early diagnosis is essential for detecting overt and sub-clinical AF.
Prompt evidence-based treatment to remediate the arrhythmia and provide appropriate anticoagulation is paramount, as these modalities directly impact disease severity and mortality. There is a significant heterogeneity in the appropriate use of oral anticoagulants and lack of adherence to guidelines in the clinical community. As the use of oral anticoagulation evolved over the last four decades several new therapies have come to being and strategies continued to evolve.
Many patients with AF are not treated according to guidelines. Projections show that by 2030, 5 million people will have new diagnosis of AF in the United States alone creating a major healthcare crisis in the cardiovascular arena.The incidence of AF related stroke will go up by 20%. administrative claims data for commercial and Medicare Advantage enrollees and Social Security Administration's death master file, 56% of hospitalized patients with a diagnosis of AF received no oral anticoagulant prescription.
However, clinicians are challenged to keep up with advances. Non-compliance with OAC ranges from 20-50% depending on the demographic. Especially, inner city, lower socioeconomic and minority groups are most impacted. Practice gaps for AF management in special populations also remain areas requiring attention, as education is needed to address disparities in care based on various social determinants of health.
Understanding the interplay of several clinical and non-clinical factors in improving early initiation, maintenance and appropriate dynamic appraisal of therapy is vital to keep the healthcare professionals deliver the highest quality of care.
